News & Updates

Real Endpoints Recent Developments

The Shrinking Value of Best-In-Class & First-In-Class Drugs

Posted by Julie Eagle on Friday, July 24, 2015

Roger Longman for In Vivo Magazine, July/August 2015 Issue Incumbency ain’t worth what it once was. Pharma companies are spending billions to create advantages that won’t have significant lasting power. Smart followers can do as well – for less. As payors struggle to...

Learn More

The Specialty Drug Price Debate: Should Medtech Be Worried?

Posted by Julie Eagle on Thursday, July 16, 2015

The Specialty Drug Price Debate: Should Medtech Be Worried? As prices for specialty drugs like oncologics soar, outrage is mounting over the cost of the new therapies.  Could any of this spill over to medical devices?  Medtech Issue, July 2015 by DAVID CASSAK As we...

Learn More

New anti-cholesterol drugs could be biggest sellers ever…how do they measure up?

Posted by Julie Eagle on Wednesday, July 8, 2015

Westport, CT, July 7, 2015 –PRESS RELEASER– RxScorecard™ analysis of the new lipid-lowering therapies, the innovative PCSK9 inhibitors for patients with difficult-to-lower, high LDL-C (bad cholesterol) levels.   According to Real Endpoints’ (RE) just-released...

Learn More

‘DrugAbacus’, a Comparative Cancer Drug Pricing Platform Powered by Real Endpoints’ RxScorecard™, is Launched

Posted by Julie Eagle on Friday, June 19, 2015

Westport, CT, June 19, 2015 – Real Endpoints (RE) is pleased to announce that its RxScorecard™ is the information technology platform supporting Memorial Sloan Kettering Cancer Center’s DrugAbacus – an interactive tool for considering the basis of cancer drug...

Learn More

Wall Street Journal publishes article on new cancer pricing tool from Memorial Sloan Kettering using RE’s RxScorecard technology

Posted by Julie Eagle on Friday, June 19, 2015

June 19, 2015 – Memorial Sloan Kettering Cancer Center, one of the nation’s top cancer hospitals, has created an interactive calculator that compares the cost of more than 50 cancer drugs with what the prices would be if they were tied to factors such as...

Learn More

ASCO accepts Real Endpoints’ abstract on RxScorecard analysis of adjuvant breast cancer therapies

Posted by Julie Eagle on Thursday, May 14, 2015

May 14, 2015 – Real Endpoints is pleased to announce that it will be presenting its RxScorecard on adjuvant breast cancer at ASCO’s annual meeting in June. The analysis demonstrates that its RxScorecard interactive, web-based tool can determine relative drug...

Learn More